NO20083033L - Anvendelse av benzofuserte heterocykliske sulfamidderivater som neurobeskyttende midler - Google Patents

Anvendelse av benzofuserte heterocykliske sulfamidderivater som neurobeskyttende midler

Info

Publication number
NO20083033L
NO20083033L NO20083033A NO20083033A NO20083033L NO 20083033 L NO20083033 L NO 20083033L NO 20083033 A NO20083033 A NO 20083033A NO 20083033 A NO20083033 A NO 20083033A NO 20083033 L NO20083033 L NO 20083033L
Authority
NO
Norway
Prior art keywords
sulfamide derivatives
neuroprotective agents
treating
formula
benzofused heterocyclic
Prior art date
Application number
NO20083033A
Other languages
English (en)
Norwegian (no)
Inventor
Allen B Reitz
Virginia L Smith-Swintosky
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37951698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083033(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20083033L publication Critical patent/NO20083033L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
NO20083033A 2005-12-19 2008-07-04 Anvendelse av benzofuserte heterocykliske sulfamidderivater som neurobeskyttende midler NO20083033L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75149405P 2005-12-19 2005-12-19
US11/612,146 US20070155823A1 (en) 2005-12-19 2006-12-18 Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
PCT/US2006/048451 WO2007075698A2 (en) 2005-12-19 2006-12-19 Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents

Publications (1)

Publication Number Publication Date
NO20083033L true NO20083033L (no) 2008-09-16

Family

ID=37951698

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083033A NO20083033L (no) 2005-12-19 2008-07-04 Anvendelse av benzofuserte heterocykliske sulfamidderivater som neurobeskyttende midler

Country Status (23)

Country Link
US (1) US20070155823A1 (sr)
EP (1) EP1968571B1 (sr)
JP (1) JP5190373B2 (sr)
KR (1) KR20080089405A (sr)
AT (1) ATE536182T1 (sr)
AU (1) AU2006331783A1 (sr)
BR (1) BRPI0620060A2 (sr)
CA (1) CA2634088A1 (sr)
CR (1) CR10171A (sr)
CY (1) CY1112444T1 (sr)
DK (1) DK1968571T3 (sr)
EA (1) EA016628B1 (sr)
ES (1) ES2375845T3 (sr)
HR (1) HRP20120018T1 (sr)
IL (1) IL192106A0 (sr)
MY (1) MY149175A (sr)
NO (1) NO20083033L (sr)
NZ (1) NZ569041A (sr)
PL (1) PL1968571T3 (sr)
PT (1) PT1968571E (sr)
RS (1) RS52220B (sr)
SI (1) SI1968571T1 (sr)
WO (1) WO2007075698A2 (sr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MX2007014613A (es) * 2005-05-20 2008-04-02 Johnson & Johnson Procedimiento para la preparacion de derivados de sulfamida.
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
WO2007137167A2 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
AU2009242095A1 (en) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
EP2271635A1 (en) * 2008-04-29 2011-01-12 NSAB, Filial af NeuroSearch Sweden AB, Sverige Modulators of dopamine neurotransmission
KR20100135325A (ko) * 2008-04-29 2010-12-24 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 도파민 신경전달의 조절제
AU2009271362B2 (en) 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
TWI406596B (zh) 2008-06-30 2013-08-21 Green Solution Tech Co Ltd 發光二極體驅動電路、發光二極體驅動控制單元及其電晶體開關模組
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
AU2012316279A1 (en) 2011-09-29 2014-04-17 Janssen Pharmaceutica Nv Process for the preparation of sulfamide derivatives
US8895762B2 (en) 2011-09-29 2014-11-25 Janssen Pharmaceutica Nv Process for the preparation of sulfamide derivatives
DK2865663T3 (en) * 2012-06-21 2017-06-19 Eisai R&D Man Co Ltd HIS UNKNOWN INDANSULPHAMIDE DERIVATIVES
BR112020017835A2 (pt) 2018-03-20 2020-12-29 Eisai R&D Management Co., Ltd. Agente de tratamento de epilepsia

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2527861A (en) * 1948-05-07 1950-10-31 Monsanto Chemicals Mono alkyl sulfamides
BE636655A (sr) * 1962-09-14
US3318952A (en) * 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3383414A (en) * 1964-08-26 1968-05-14 Sandoz Ag Benzocycloalkyl sulfamides
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
US5212326A (en) * 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
FR2479825A1 (fr) * 1980-04-04 1981-10-09 Fabre Sa Pierre Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5273993A (en) * 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
US5194446A (en) * 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5192785A (en) * 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
IL103172A (en) * 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) * 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
CA2216648A1 (en) * 1995-02-15 1996-08-22 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor
JP3235448B2 (ja) * 1995-03-24 2001-12-04 ダイソー株式会社 １，４−ベンゾジオキサン誘導体の製法
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
AU1328197A (en) * 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
EP0915697B1 (en) * 1996-06-28 2002-09-18 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
EP0942752B1 (en) * 1996-08-23 2005-04-20 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US5935933A (en) * 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
AU9021298A (en) * 1997-08-15 1999-03-08 Carolyn Ann Fairbanks Agmatine as a treatment for neuropathic pain
CZ20012620A3 (cs) * 1999-01-19 2002-09-11 Ortho-Mcneil Pharmaceutical, Inc. Léčivo pro léčení histaminové cefalalgie
CA2364949A1 (en) * 1999-02-24 2000-08-31 University Of Cincinnati Use of sulfamate derivatives for treating impulse control disorders
MXPA01010218A (es) * 1999-04-08 2002-03-27 Johnson & Johnson Derivados anticonvulsivos utiles para disminuir lipidos.
US6583172B1 (en) * 1999-04-08 2003-06-24 Richard P. Shank Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
US6562865B1 (en) * 1999-08-20 2003-05-13 Ortho-Mcneil Pharmaceutical, Inc. Composition comprising a tramadol material and an anticonvulsant drug
US6322503B1 (en) * 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
PT1309324E (pt) * 2000-07-07 2006-06-30 Ortho Mcneil Pharm Inc Derivados de anticonvulsivos uteis para o tratamento e prevencao do desenvolvimento de diabetes mellitus do tipo ii e da sindroma x
CA2417304A1 (en) * 2000-08-02 2002-02-07 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
EP1357908A4 (en) * 2001-01-30 2009-07-15 Merck & Co Inc "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS"
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US6949518B1 (en) * 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
US20060276528A1 (en) * 2004-08-24 2006-12-07 Abdel-Magid Ahmed F Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
MX2007002309A (es) * 2004-08-24 2007-10-08 Johnson & Johnson Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
KR20080009295A (ko) * 2005-04-22 2008-01-28 와이어쓰 벤조디옥산 및 벤조디옥솔란 유도체 및 이의 용도
MX2007014613A (es) * 2005-05-20 2008-04-02 Johnson & Johnson Procedimiento para la preparacion de derivados de sulfamida.
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US20070293476A1 (en) * 2006-05-19 2007-12-20 Smith-Swintosky Virginia L Co-therapy for the treatment of epilepsy and related disorders
WO2007137167A2 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
WO2009089210A1 (en) * 2008-01-07 2009-07-16 Janssen Pharmaceutica N. V. Preparation of sulfamide derivatives
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247618A1 (en) * 2008-03-26 2009-10-01 Ballentine Scott A Process for preparation of benzo-fused heteroaryl derivatives
AU2009271362B2 (en) * 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives

Also Published As

Publication number Publication date
HK1124544A1 (en) 2009-07-17
RS52220B (sr) 2012-10-31
AU2006331783A1 (en) 2007-07-05
BRPI0620060A2 (pt) 2011-11-01
MY149175A (en) 2013-07-31
WO2007075698A2 (en) 2007-07-05
ATE536182T1 (de) 2011-12-15
CY1112444T1 (el) 2015-12-09
KR20080089405A (ko) 2008-10-06
PT1968571E (pt) 2012-02-01
ES2375845T3 (es) 2012-03-06
EP1968571B1 (en) 2011-12-07
JP5190373B2 (ja) 2013-04-24
DK1968571T3 (da) 2012-02-27
HRP20120018T1 (hr) 2012-01-31
SI1968571T1 (sl) 2012-03-30
IL192106A0 (en) 2009-08-03
WO2007075698A3 (en) 2007-08-16
EA200870087A1 (ru) 2009-12-30
NZ569041A (en) 2011-04-29
CR10171A (es) 2009-01-16
JP2009520031A (ja) 2009-05-21
EA016628B1 (ru) 2012-06-29
EP1968571A2 (en) 2008-09-17
CA2634088A1 (en) 2007-07-05
PL1968571T3 (pl) 2012-04-30
US20070155823A1 (en) 2007-07-05

Similar Documents

Publication Publication Date Title
NO20083033L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater som neurobeskyttende midler
WO2007095618A3 (en) Benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2007095613A3 (en) Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
NO20083004L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av stoffmisbrukavhengighet
NO20072665L (no) Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser
ATE384058T1 (de) Thiazolderivate
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
BRPI0921692A2 (pt) composto carbamato ou o sal do mesmo
SI1973540T1 (sl) Uporaba benzokondenziranih heterocikličnih sulafamidnih derivatov za zdravljenje bolečine
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
SI1973539T1 (sl) Uporaba benzokondenziranih heterocikličnih sulfamidnih derivatov za zdravljenje depresije
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
MY145823A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
WO2007095611A3 (en) Use of benzo-fused heteroaryl sulfamide derivatives for the treatment of migraine
WO2007095609A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder
UA96747C2 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных как нейропротективных агентов
UA95094C2 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства
UA100552C2 (ru) Применение гетероциклических бензопроизводных сульфамида для лечения тревожных расстройств
ATE502947T1 (de) 4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren
TH94294A (th) การใช้อนุพันธ์เบนโซ-ฟิวเซด เฮเทอโรไซเคิล ซัลฟาไมด์ เป็นสารป้องกันการทำลายเซลล์ประสาทในสมอง
UY30157A1 (es) Uso de derivados de benzo-heteroaril sulfamida como agentes neuroprotectores
UA97106C2 (ru) Применение производных бензоконденсированного гетероциклического сульфамида для лечения злоупотребления психоактивным веществом и аддикции

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application